In Vivo Targeting Replication Protein A for Cancer Therapy
暂无分享,去创建一个
Navnath S. Gavande | S. Jalal | J. Turchi | K. Pollok | S. Patrick | Joshua R. Heyza | K. Pawelczak | Elmira Ekinci | P. VanderVere-Carozza | Andi Masters | Joshua R Heyza
[1] C. Lord,et al. Targeting the DNA damage response in immuno-oncology: developments and opportunities , 2021, Nature Reviews Cancer.
[2] S. Cantor,et al. Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency. , 2021, Molecular cell.
[3] J. Soria,et al. Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study , 2021, Clinical Cancer Research.
[4] S. Cantor,et al. Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency. , 2021, Molecular cell.
[5] Navnath S. Gavande,et al. Chemical exhaustion of RPA in cancer treatment , 2020, bioRxiv.
[6] Navnath S. Gavande,et al. Discovery and development of novel DNA-PK inhibitors by targeting the unique Ku–DNA interaction , 2020, bioRxiv.
[7] Navnath S. Gavande,et al. Discovery and Development of Novel DNA-PK Inhibitors by Targeting the unique Ku-DNA Interaction , 2020, bioRxiv.
[8] Navnath S. Gavande,et al. Structure-Guided Optimization of Replication Protein A (RPA)-DNA Interaction Inhibitors. , 2020, ACS medicinal chemistry letters.
[9] A. A. Demin,et al. The Importance of Poly(ADP-Ribose) Polymerase as a Sensor of Unligated Okazaki Fragments during DNA Replication , 2018, Molecular cell.
[10] B. Goh,et al. Third generation EGFR TKIs: current data and future directions , 2018, Molecular Cancer.
[11] Navnath S. Gavande,et al. Modulating DNA Repair Pathways to Improve Precision Genome Engineering. , 2017, ACS chemical biology.
[12] Navnath S. Gavande,et al. Design and Structure-Guided Development of Novel Inhibitors of the Xeroderma Pigmentosum Group A (XPA) Protein-DNA Interaction. , 2017, Journal of medicinal chemistry.
[13] J. Lukas,et al. Replication Catastrophe: When a Checkpoint Fails because of Exhaustion. , 2017, Molecular cell.
[14] R. Schwab,et al. The DNA fibre technique - tracking helicases at work. , 2016, Methods.
[15] H. Zhang,et al. Identification of small molecule inhibitors of ERCC1-XPF that inhibit DNA repair and potentiate cisplatin efficacy in cancer cells , 2016, Oncotarget.
[16] J. Debreczeni,et al. Cellular Active N-Hydroxyurea FEN1 Inhibitors Block Substrate Entry to the Active Site , 2016, Nature chemical biology.
[17] Navnath S. Gavande,et al. DNA repair targeted therapy: The past or future of cancer treatment? , 2016, Pharmacology & therapeutics.
[18] Alan Ashworth,et al. Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors. , 2015, Annual review of medicine.
[19] N. Mailand,et al. ATR Prohibits Replication Catastrophe by Preventing Global Exhaustion of RPA , 2013, Cell.
[20] M. Dimopoulos,et al. Replication Protein A in Nonearly Ovarian Adenocarcinomas: Correlation With MCM-2, MCM-5, Ki-67 Index and Prognostic Significance , 2012, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[21] S. Jalal,et al. Novel Irreversible Small Molecule Inhibitors of Replication Protein A Display Single-Agent Activity and Synergize with Cisplatin , 2011, Molecular Cancer Therapeutics.
[22] P. Korkolopoulou,et al. Prognostic significance of replication protein A (RPA) expression levels in bladder urothelial carcinoma , 2011, BJU international.
[23] J. Turchi,et al. Targeting the OB-Folds of Replication Protein A with Small Molecules , 2010, Journal of nucleic acids.
[24] J. Turchi,et al. Identification of novel small molecule inhibitors of the XPA protein using in silico based screening. , 2010, ACS chemical biology.
[25] J. Turchi,et al. Targeted inhibition of Replication Protein A reveals cytotoxic activity, synergy with chemotherapeutic DNA-damaging agents, and insight into cellular function. , 2010, Cancer research.
[26] T. Helleday,et al. Hydroxyurea-Stalled Replication Forks Become Progressively Inactivated and Require Two Different RAD51-Mediated Pathways for Restart and Repair , 2010, Molecular cell.
[27] G. Simon. Individualizing Chemotherapy for Non-small Cell Lung Cancer (NSCLC) in the Adjuvant and Advanced Setting: Current Status and Future Directions , 2008, Current treatment options in oncology.
[28] A. Mason,et al. Cellular Functions of Human RPA1 , 2008, Journal of Biological Chemistry.
[29] G. Kouraklis,et al. Replication protein A is an independent prognostic indicator with potential therapeutic implications in colon cancer , 2007, Modern Pathology.
[30] Hongbing Shen,et al. Smoking, DNA repair capacity and risk of nonsmall cell lung cancer , 2003, International journal of cancer.
[31] M. Spitz,et al. Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study. , 2000, Journal of the National Cancer Institute.
[32] T. Taguchi,et al. [Phase I study]. , 1995, Gan to kagaku ryoho. Cancer & chemotherapy.
[33] J. Turchi,et al. Chemical inhibitor targeting the replication protein A-DNA interaction increases the efficacy of Pt-based chemotherapy in lung and ovarian cancer. , 2015, Biochemical pharmacology.
[34] Stuart Moss,et al. Current Status and Future Directions , 2013 .